Seres Therapeutics (MCRB) Enterprise Value (2016 - 2025)
Seres Therapeutics (MCRB) has disclosed Enterprise Value for 11 consecutive years, with -$45.8 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 48.62% to -$45.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.8 million through Dec 2025, down 48.62% year-over-year, with the annual reading at -$45.8 million for FY2025, 48.62% down from the prior year.
- Enterprise Value hit -$45.8 million in Q4 2025 for Seres Therapeutics, up from -$47.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$30.8 million in Q4 2024 to a low of -$473.1 million in Q3 2021.
- Historically, Enterprise Value has averaged -$179.4 million across 5 years, with a median of -$148.9 million in 2023.
- Biggest five-year swings in Enterprise Value: crashed 497.61% in 2021 and later skyrocketed 75.94% in 2024.
- Year by year, Enterprise Value stood at -$290.7 million in 2021, then surged by 37.62% to -$181.3 million in 2022, then increased by 29.43% to -$128.0 million in 2023, then soared by 75.94% to -$30.8 million in 2024, then plummeted by 48.62% to -$45.8 million in 2025.
- Business Quant data shows Enterprise Value for MCRB at -$45.8 million in Q4 2025, -$47.6 million in Q3 2025, and -$45.4 million in Q2 2025.